DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows: Date: Monday, May 13, 2024 Time: 10:00am ET Webcast: Click Here To schedule a 1x1 meeting with the Company, please contact ...

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). In addition to taking live questions from participants on the confe ...

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on de ...

财务数据和关键指标变化 - 2023年第四季度收入为7.3亿美元,同比增长109% [8][24] - 2023年全年收入达到26亿美元,较2022年增长超过130% [6] - 2023年第四季度毛利率在60%-65%之间,预计未来会随着ALKINDI和ET-400占比提高而继续提升 [31] - 2023年第四季度运营现金流为正,预计2024年将实现GAAP净利润 [9][26] 各条业务线数据和关键指标变化 - ALKINDI SPRINKLE销售持续稳定增长,预计未来几年仍有较大增长空间 [9][10] - Carglumic Acid在上市两年内已占据超过50%的市场份额,预计2024年仍将保持良好增长 [11] - Betaine销售增长较慢,但作为进入代谢科专科医生的重要工具 [12][13] - Nitisinone上月刚刚上市,已有多名患者加入,预计将占据该50亿美元市场的较大份额 [14] 公司战略和发展方向 - 继续推进ET-400和ET-600管线,ET-400有望在2025年上半年获批上市 [15][17] - 正在探索新的潜在开发项目,将在未来公布 [19] - 积极进行业务并购,有信心在2024年完成一笔收入贡献型的交易 [33] - 保持良好的财务状况,有望在2024年实现GAAP净利润 [21][22] 管理层对经营环境和未来前景的评论 - 2023年取得了多项重要里程碑,对2024年前景充满信心 [6][20] - 行业内存在较多机会,公司有能力把握并从中获益 [22] - 对ET-400和ET-600的临床进展以及未来上市前景保持乐观 [15][17]

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -125%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.02, delivering a surprise of 80%. Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 37-1858472 (State or o ...

Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results ● Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth ● Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 ● Announced successful results from ET-400’s pivotal bioequivalence study, NDA submission planned for Q2 2024 ● Management to hold co ...

DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here In addition t ...

公司概况 - Eton Pharmaceuticals是一家专注于开发和商业化罕见疾病治疗药物的创新制药公司[5] 财务业绩 - 公司将于2024年3月14日公布2023年第四季度和全年财务业绩[1] 投资者沟通 - 投资者可以通过电子邮件向公司投资者关系部门发送问题，公司将回答这些问题[2] - 公司网站的投资者部分提供了直播网络研讨会的链接，以及活动结束后约两小时内和之后30天内的存档网络研讨会[3] - 参加电话会议的与会者应注册以获取拨入和密码详细信息[4]

DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has granted the Company's U.S. Patent Application No. 18/113,458, which covers the Company's ET-400 product candidate's proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 a ...